{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:01:51Z","timestamp":1792425711441,"version":"4.5.0"},"reference-count":27,"publisher":"eLife Sciences Publications, Ltd","license":[{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1092240"],"award-info":[{"award-number":["OPP1092240"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["NIHR: PR-OD-1017-20002"],"award-info":[{"award-number":["NIHR: PR-OD-1017-20002"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/R015600\/1"],"award-info":[{"award-number":["MR\/R015600\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000288","name":"Royal Society","doi-asserted-by":"publisher","award":["Sir Henry Dale Fellowship grant 213494\/Z\/18\/Z"],"award-info":[{"award-number":["Sir Henry Dale Fellowship grant 213494\/Z\/18\/Z"]}],"id":[{"id":"10.13039\/501100000288","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["Sir Henry Dale Fellowship grant 213494\/Z\/18\/Z"],"award-info":[{"award-number":["Sir Henry Dale Fellowship grant 213494\/Z\/18\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elifesciences.org"],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec id=\"abs1\">\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Sanofi-Pasteur\u2019s CYD-TDV is the only licensed dengue vaccine. Two phase three trials showed higher efficacy in seropositive than seronegative recipients. Hospital follow-up revealed increased hospitalisation in 2\u20135- year-old vaccinees, where serostatus and age effects were unresolved.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs2\">\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We fit a survival model to individual-level data from both trials, including year 1 of hospital follow-up. We determine efficacy by age, serostatus, serotype and severity, and examine efficacy duration and vaccine action mechanism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs3\">\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Our modelling indicates that vaccine-induced immunity is long-lived in seropositive recipients, and therefore that vaccinating seropositives gives higher protection than two natural infections. Long-term increased hospitalisation risk outweighs short-lived immunity in seronegatives. Independently of serostatus, transient immunity increases with age, and is highest against serotype 4. Benefit is higher in seropositives, and risk enhancement is greater in seronegatives, against hospitalised disease than against febrile disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs4\">\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Our results support vaccinating seropositives only. Rapid diagnostic tests would enable viable \u2018screen-then-vaccinate\u2019 programs. Since CYD-TDV acts as a silent infection, long-term safety of other vaccine candidates must be closely monitored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs5\">\n                    <jats:title>Funding:<\/jats:title>\n                    <jats:p>Bill &amp; Melinda Gates Foundation, National Institute for Health Research, UK Medical Research Council, Wellcome Trust, Royal Society.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs6\">\n                    <jats:title>Clinical trial number:<\/jats:title>\n                    <jats:p>\n                      <jats:related-object document-id=\"NCT01373281\" document-id-type=\"clinical-trial-number\" id=\"RO1\" source-id=\"ClinicalTrials.gov\" source-id-type=\"registry-name\" source-type=\"clinical-trials-registry\" xlink:href=\"https:\/\/clinicaltrials.gov\/show\/NCT01373281\">NCT01373281<\/jats:related-object>\n                      and\n                      <jats:related-object document-id=\"NCT01374516\" document-id-type=\"clinical-trial-number\" id=\"RO2\" source-id=\"ClinicalTrials.gov\" source-id-type=\"registry-name\" source-type=\"clinical-trials-registry\" xlink:href=\"https:\/\/clinicaltrials.gov\/show\/NCT01374516\">NCT01374516<\/jats:related-object>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.7554\/elife.65131","type":"journal-article","created":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T08:01:14Z","timestamp":1625212874000},"update-policy":"https:\/\/doi.org\/10.7554\/elife.65131","source":"Crossref","is-referenced-by-count":20,"title":["Efficacy profile of the CYD-TDV dengue vaccine revealed by Bayesian survival analysis of individual-level phase III data"],"prefix":"10.7554","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct01373281","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01374516","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4270-3321","authenticated-orcid":true,"given":"Daniel J","family":"Laydon","sequence":"first","affiliation":[{"name":"MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, Faculty of Medicine, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9959-0706","authenticated-orcid":true,"given":"Ilaria","family":"Dorigatti","sequence":"additional","affiliation":[{"name":"MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, Faculty of Medicine, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wes R","family":"Hinsley","sequence":"additional","affiliation":[{"name":"MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, Faculty of Medicine, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Nedjati-Gilani","sequence":"additional","affiliation":[{"name":"MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, Faculty of Medicine, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Coudeville","sequence":"additional","affiliation":[{"name":"Sanofi Pasteur, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil M","family":"Ferguson","sequence":"additional","affiliation":[{"name":"MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, Faculty of Medicine, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4374","published-online":{"date-parts":[[2021,7,2]]},"reference":[{"key":"bib1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-45816-6","article-title":"Cross-serotype interactions and disease outcome prediction of dengue infections in Vietnam","volume":"9","author":"Aguas","year":"2019","journal-title":"Scientific Reports"},{"key":"bib2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30752-1","article-title":"Dengvaxia: age as surrogate for serostatus","volume":"18","author":"Aguiar","year":"2018","journal-title":"The Lancet Infectious Diseases"},{"key":"bib3","volume-title":"On the Derivation of the Bayesian Information Criterion School of Natural Sciences","author":"Bhat","year":"2010"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"The Lancet"},{"key":"bib5","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax4144","article-title":"Mapping global variation in dengue transmission intensity","volume":"12","author":"Cattarino","year":"2020","journal-title":"Science Translational Medicine"},{"key":"bib6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1004951","article-title":"Modelling virus and antibody dynamics during dengue virus infection suggests a role for antibody in virus clearance","volume":"12","author":"Clapham","year":"2016","journal-title":"PLOS Computational Biology"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1109\/99.660313","article-title":"OpenMP: an industry standard API for shared-memory programming","volume":"5","author":"Dagum","year":"1998","journal-title":"IEEE Computational Science and Engineering"},{"key":"bib8","doi-asserted-by":"publisher","first-page":"4848","DOI":"10.1016\/j.vaccine.2018.09.063","article-title":"Dengue vaccine: who position paper, September 2018 \u2013 Recommendations","volume":"37","author":"Dengue vaccine","year":"2019","journal-title":"Vaccine"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-06006-6","article-title":"Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning","volume":"9","author":"Dorigatti","year":"2018","journal-title":"Nature Communications"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1126\/science.aaf9590","article-title":"Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment","volume":"353","author":"Ferguson","year":"2016","journal-title":"Science"},{"key":"bib11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002181","article-title":"The Long-Term safety, public health impact, and Cost-Effectiveness of routine vaccination with a recombinant, Live-Attenuated dengue vaccine (Dengvaxia): A model comparison study","volume":"13","author":"Flasche","year":"2016","journal-title":"PLOS Medicine"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S1473-3099(19)30167-7","article-title":"Sensitivity and negative predictive value for a rapid dengue test","volume":"19","author":"Flasche","year":"2019","journal-title":"The Lancet Infectious Diseases"},{"key":"bib13","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1038\/nrmicro2460","article-title":"Dengue: a continuing global threat","volume":"8","author":"Guzman","year":"2010","journal-title":"Nature Reviews Microbiology"},{"key":"bib14","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and Long-Term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"bib15","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1126\/science.aan6836","article-title":"Antibody-dependent enhancement of severe dengue disease in humans","volume":"358","author":"Katzelnick","year":"2017","journal-title":"Science"},{"key":"bib16","article-title":"Dengue vaccine trial survival model","volume-title":"Software Heritage","author":"Laydon","year":"2021","unstructured":"Laydon DJ. 2021. Dengue vaccine trial survival model. Software Heritage. swh:1:rev:d4964b7240312a371b2767533099643c59025dbf. https:\/\/archive.softwareheritage.org\/swh:1:rev:d4964b7240312a371b2767533099643c59025dbf."},{"key":"bib17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jviromet.2018.03.007","article-title":"Development of an anti-dengue NS1 IgG ELISA to evaluate exposure to dengue virus","volume":"257","author":"Nascimento","year":"2018","journal-title":"Journal of Virological Methods"},{"key":"bib18","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1093\/infdis\/jiw297","article-title":"Tetravalent dengue vaccine reduces symptomatic and asymptomatic dengue virus infections in healthy children and adolescents aged 2\u201316 Years in Asia and Latin America","volume":"214","author":"Olivera-Botello","year":"2016","journal-title":"Journal of Infectious Diseases"},{"key":"bib19","article-title":"R: A Language and Environment for Statistical Computing","author":"R Development Core Team","year":"2019","unstructured":"R Development Core Team. 2019. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing. http:\/\/www.r-project.org."},{"key":"bib20","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/S0140-6736(12)61428-7","article-title":"Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial","volume":"380","author":"Sabchareon","year":"2012","journal-title":"The Lancet"},{"key":"bib21","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41586-018-0157-4","article-title":"Reconstruction of antibody dynamics and infection histories to evaluate dengue risk","volume":"557","author":"Salje","year":"2018","journal-title":"Nature"},{"key":"bib22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"bib23","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41577-019-0123-x","article-title":"Adaptive immune responses to primary and secondary dengue virus infections","volume":"19","author":"St John","year":"2019","journal-title":"Nature Reviews Immunology"},{"key":"bib24","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/S1473-3099(16)00026-8","article-title":"The global burden of dengue: an analysis from the global burden of disease study 2013","volume":"16","author":"Stanaway","year":"2016","journal-title":"The Lancet Infectious Diseases"},{"key":"bib25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"bib26","first-page":"867","article-title":"A widely applicable bayesian information criterion","volume":"14","author":"Watanabe","year":"2013","journal-title":"Journal of Machine Learning Research"},{"key":"bib27","first-page":"17","article-title":"Global advisory committee on vaccine safety, 6\u20137 December 2017\u2013Comit\u00e9 consultatif mondial pour la s\u00e9curit\u00e9 des vaccins, 6-7 d\u00e9cembre 2017","volume":"93","author":"WHO","year":"2018","journal-title":"Weekly Epidemiological Record= Relev\u00e9 \u00c9pid\u00e9miologique Hebdomadaire"}],"container-title":["eLife"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.elifesciences.org\/articles\/65131\/elife-65131-v3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/cdn.elifesciences.org\/articles\/65131\/elife-65131-v3.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/elifesciences.org\/articles\/65131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T21:07:52Z","timestamp":1697058472000},"score":1,"resource":{"primary":{"URL":"https:\/\/elifesciences.org\/articles\/65131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,2]]},"references-count":27,"alternative-id":["10.7554\/eLife.65131"],"URL":"https:\/\/doi.org\/10.7554\/elife.65131","archive":["CLOCKSS"],"relation":{"has-review":[{"id-type":"doi","id":"10.7554\/eLife.65131.sa1","asserted-by":"object"},{"id-type":"doi","id":"10.7554\/eLife.65131.sa2","asserted-by":"object"}]},"ISSN":["2050-084X"],"issn-type":[{"value":"2050-084X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,2]]},"assertion":[{"value":"single anonymised","name":"peer_review_transparency","label":"Peer review transparency","group":{"name":"peer_review_taxonomy"}},{"value":"other reviewer(s), editor","name":"peer_review_interaction","label":"Peer review interaction","group":{"name":"peer_review_taxonomy"}},{"value":"review summaries, review reports, author\/editor communication, reviewer identities reviewer opt in, editor identities","name":"peer_review_published","label":"Peer review published","group":{"name":"peer_review_taxonomy"}},{"value":"open (sign in with ORCID iD required)","name":"post_publication_commenting","label":"Post publication commenting","group":{"name":"post_publication_commenting"}}],"article-number":"e65131"}}